Correvio is a global pharmaceutical brand that strives to improve the lives of patients by providing specialty, hospital, and rare disease medicines. As a partner of choice for the commercialization of these medicines in Europe, Canada, and Australia, Correvio is dedicated to bringing innovation to patients through collaborations with biopharma and pharmaceutical development companies. With headquarters in London, UK, Correvio has a strong presence in over 90 countries and direct commercial operations in more than 20 countries.

Their portfolio and pipeline encompass a wide range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and rare diseases. Correvio's product offerings consist of innovative medicines, specialty generics & biosimilars, and originator brands. From Ocaliva®, a rare disease medicine for the treatment of Primary Biliary Cholangitis, to Mytolac®/Myrelez®, a synthetic hormone used in the treatment of neuroendocrine tumors, Correvio's goal is to provide safe, effective, and high-quality medications.

With a team of dedicated professionals who value entrepreneurship, speed, and integrity, Correvio is committed to making a difference in patients' lives by ensuring access to essential medicines